Navigation Links
Precision Therapeutics Demonstrates Utility of Multi-Gene Predictors in Predicting Chemotherapy Response for Breast Cancer Patients
Date:6/6/2011

PITTSBURGH, June 6, 2011 /PRNewswire/ -- Precision Therapeutics, Inc. demonstrated data supporting the utility of cell line-derived multi-gene predictors in the prediction of preoperative chemotherapy response in early stage breast cancer at the 2011 ASCO Annual Meeting on June 4, 2011 in Chicago, Illinois.  The study, titled, Multigene Predictors Developed on Breast Cancer Cell Lines to Predict Patient Chemotherapy Response:  A Validation Study on the NSABP B-27 Trial, combined the genomic profiles of cell lines with their in vitro chemoresponse data to identify genes whose expression was associated with drug response.  The resulting MGP was used to predict chemotherapy response in patients.

"Clinical interests currently lie in identifying patients most responsive to specific chemotherapy agents to maximize the benefit of treatment and to minimize unnecessary side effects," stated Kui Shen, Ph.D., a bioinformatics scientist and co-author of the study. "By combining ChemoFx® chemosensitivity data from cell lines with their genomic profiles, Precision has developed a procedure to derive gene signatures that may predict a patient's chemotherapy response prior to treatment. This approach is now confirmed using NSABP B-27 clinical data, showing an accuracy of as high as 75%."

Precision continues to seek and develop strategic products that fit within the cancer care continuum, including multi-gene predictors to help with choosing treatments for triple negative women.  Precision has completed 12 separate validations including both NSABP and U.S. Oncology trials.

About Precision Therapeutics

Precision Therapeutics, a leading life-science company based in Pittsburgh, Pennsylvania, is dedicated to personalized cancer care.  Precision offers a portfolio of products developed to help guide physicians and patients with difficult clinical decisions throughout the cancer care continuum.

Precision's state of the art bioinformatics combined with the analysis of the live molecular, proteomic and genomic activity of each patient's cancer offer an innovative foundation for further development and commercialization of novel predictive markers for cancer therapy. 

About ChemoFx®

Precision's first commercial test, ChemoFx®, is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician. For more information, please visit www.precisiontherapeutics.com, or www.chemofx.com.


'/>"/>
SOURCE Precision Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. TechPrecision Corporation Receives $1.6 Million in New Orders from Existing Customers
2. Volcano to Highlight its Precision Guided Therapy Technologies at EuroPCR
3. Robotic Couch Provides Extra Degree of Precision for Patients Undergoing Radiation Therapy for Cancer
4. Boston Scientific Receives FDA Approval of New Clik(TM) Anchor for Precision Plus(TM) Spinal Cord Stimulator System
5. Source Precision Medicine, Inc. d/b/a Source MDx Announces Foundational Patents Will Be Offered for Sale on April 29, 2011
6. Source Precision Medicine, Inc., dba SourceMDx Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. of the firm of Finn, Warnke & Gayton, LLP
7. Applied Precision Exhibit at the Biophysical Society Annual Meeting Showcases New Microscopy Solutions for Life Science Industries
8. TechPrecision Corporation Receives New $450,000 Medical Purchase Order
9. Applied Precision Scientific Team to Present 3D-SIM Paper at BiOS in San Francisco
10. Abbott Diabetes Care Announces Recall of Certain Lots of Precision Xtra®, Precision Xceed Pro®, MediSense® Optium™, Optium™, OptiumEZ and ReliOn® Ultima Blood Glucose Test Strips in the United States and Puerto Rico
11. Exempla Saint Joseph Hospital Commences Treating Cancer Patients Using New TrueBeam™ System for High-Precision Image-Guided Radiotherapy and Radiosurgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... --  Divoti USA will engrave and process all ... the latest FDA requirements, which stipulates new criteria regarding medical device ... of Medical ID jewelry such as Medical ID Bracelets, can rest ... terms of the new FDA requirements . ... Divoti offers this dark mark fiber laser engraving ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ... on fulfilling the promise of precision medicine, today announced ... joined Caris, Precision Oncology Alliance™ (POA) as its 17 ... centers, the St. Jude Crosson Cancer Institute will help ... the use of tumor profiling, making cancer treatment more ...
(Date:10/10/2017)... ORANGE COUNTY, Calif. , Oct. 10, 2017  NDS received ... Mobile  — a medical-grade battery-powered display stand specifically designed for ... aims to transform technology into a clinical solution to support the ... costs. Innovative Design ... NDS ZeroWire Mobile Wireless Solution ...
Breaking Medicine Technology:
(Date:10/13/2017)... WI (PRWEB) , ... October 13, 2017 , ... As ... in medicine known as “patient engagement.” The patient is doing more than filling out ... partners. , “There is an increasing emphasis in health care and research on ...
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association of ... of excellence for the field of eating disorders, announces the opening of early ... in Orlando, Florida at the Omni Resort at ChampionsGate. , The ...
(Date:10/13/2017)... ... 13, 2017 , ... Lori R. Somekh, founder of the Law Office ... of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our office ... forum to network with elder law attorneys nationwide,” said Somekh. , ElderCounsel ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The Visiting ... Day Market. Featuring a collection of specialty vendors and unique items from across the ... and quality-focused health and wellness services offered by the VNA. The boutique will ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
Breaking Medicine News(10 mins):